NOVEL LACTIC ACID BACTERIA AND COMPOSITIONS CONTAINING THEM AGAINST BACTERIAL COLDS

• US 20140065218A1
• Filed: 05/16/2012
• Published: 03/06/2014
• Est. Priority Date: 05/16/2011
• Status: Active Grant

• Current Assignee: Organobalance Medical AG
• Original Assignee: Organobalance Medical AG
• Inventors: Lang, Christine, Raab, Andreas, Bolotina, Natalia
• Granted Patent: US 9,308,227 B2
• Time in Patent Office: Days
• US Class Current: 424/474
• CPC Class Codes: A23K 10/16 Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions A23K10/12 takes precedence
• CPC Class Codes: A23K 10/18 of live microorganisms
• CPC Class Codes: A23L 33/135 Bacteria or derivatives thereof, e.g. probiotics
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/08 Food product presented as a kit of parts
• CPC Class Codes: A23V 2200/318 having an effect on skin health and hair or coat
• CPC Class Codes: A23V 2200/3204 Probiotics, living bacteria to be ingested for action in the digestive tract
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61K 35/744 Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 1/20 Bacteria; Culture media therefor
• CPC Class Codes: C12N 1/205 Bacterial isolates
• CPC Class Codes: C12Q 1/04 Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor C12Q1/6897 takes precedence
• CPC Class Codes: C12R 2001/225 Lactobacillus

Abstract

The invention describes a microorganism of the order of lactic acid bacteria or an analogue, fragment, derivative, mutant or combination thereof, wherein the microorganism, or analogue, fragment, derivative, mutant or combination thereof can coaggregate with Streptococcus pyogenes.

Claims

1. A microorganism of the lactic acid bacterium order or an analog, fragment, derivative, mutant or combinations thereof, wherein the microorganism, analog, fragment, derivative, mutant or combination thereof has the cabability of coaggregating with at least one pathogenic microorganism, wherein the pathogenic microorganism is Streptococcus pyogenes.

2. The microorganism or the analog, fragment, derivative, mutant or combination thereof according to claim 1, wherein the microorganisms belongs to the Lactobacillus genus.

3. The method of claim 41, wherein the microorganism of the lactic acid bacterium order or an analog, fragment, derivative, mutant or combinations thereof coaggregates with the pathogenic microorganism even after a biological, chemical or physical treatment.

4. The method of claim 41 wherein the microorganism of the lactic acid bacterium order or an analog, fragment, derivative, mutant or combinations thereof coaggregates with the pathogenic microorganism at a pH between approximately 3 and approximately 8.

5. The method of claim 41, wherein the microorganism or analog, fragment, derivative, mutant or combinations thereof inhibits the formation of a biofilm of the pathogenic microorganism.

6. The method of claim 41, wherein the microorganism or analog, fragment, derivative, mutant or combinations thereof prevents binding of fibronectin by Streptococcus pyogenes.

7. The method of claim 41, wherein the microorganism or analog, fragment, derivative, mutant or combinations thereof does not coaggregate with any commensal microorganism of the skin or mucous membranes.

8. The microorganism or an analog, fragment, derivative, mutant or combinations thereof according to claim 1, wherein the microorganism is Lactobacillus lactis, Lactobacillus helveticus, Lactobacillus jensenii, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus amylovorus, Lactobacillus delbrueckii, Lactobacillus casei, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus paracasei, Lactobacillus pentosus, Lactobacillus rhamnosus, Lactobacillus curvatus, Lactobacillus plantarum, Lactobacillus brevis, Lactobacillus buchneri, Lactobacillus fructivorans, Lactobacillus hilgardii, Lactobacillus fermentum, Lactobacillus reuteri, Lactobacillus viridescens, Bifidobacterium bifidum, Lactobacillus ingluviei or analogs, derivatives, fragments or mutants thereof.

9. The microorganism or an analog, fragment, derivative, mutant or combination thereof according to claim 1, wherein the microorganism is selected from the group consisting of the following microorganisms that have been deposited with the German Collection for Microorganisms and Cell Cultures and have been numbered as DSM 25972, DSM 25987, DSM 25988, DSM 25989 and DSM 25973.

10. A composition comprising at least one microorganism or analog, fragment, derivative, mutant or combination thereof according to claim 1, optionally comprising a pharmaceutically or cosmetically acceptable vehicle or excipient.

12. The composition according to claim 10, wherein the composition is in a solid, liquid or viscous form or is an aerosol, or wherein the composition is in the form of a paste, a soft gelatin capsule, hard gelatin capsule, powder, granules, beads, pastilles, effervescent tablet, lozenge, buccal tablet, chewable tablet, sublingual tablet, solution, tincture, emulsion, juice, concentrate, syrup, spray, drinking ampoule, gel, mouth wash, toothpaste, chewing gum, tablet, coated pill or bonbon.

14. The composition according to claim 10, wherein the composition comprises probiotics, antiseptics or other antibacterial substances.

15. The composition according to claim 10, wherein the composition is a pharmaceutical, veterinary or cosmetic composition or a food supplement or a food supplement composition.

16. The composition according to claim 10 additionally comprising one or more of the following substances:

antioxidants, vitamins, coenzymes, fatty acids, amino acids and/or cofactors and/or one or more thickeners, one or more sweeteners and/or one or more artificial sweeteners.

18. The composition according to claim 16, wherein the thickener is selected from the group consisting of cellulose ether, polysaccharides, selected from the group comprising xanthan gum, gelatin, highly-disperse silicon dioxide, starch, alginates, tragacanth, agar, gum arabic, pectin and polyvinyl ester and the sweetener is selected from the group consisting of glucose, fructose, sucrose and glucose syrup, sorbitol, mannitol, xylitol and maltitol, saccharine, sodium cyclamate, acesulfame K, aspartame and combinations thereof.

19. The composition according to claim 10 additionally comprising builder substances, enzymes, electrolytes, pH regulators, thickeners, soil release agents, optical brighteners, graying inhibitors, dye transfer inhibitors, film regulators and/or coloring agents.

20. The composition according to claim 10, wherein the microorganism is present as a viable or killed microorganism in the composition and/or is in encapsulated, spray-dried and/or lyophilized form and/or in form of a cell lysate.

23. The composition according to claim 10, wherein the microorganism is present in an amount of 0.001 wt % to 20 wt %, preferably 0.005 wt % to 10 wt %, especially preferably 0.01 wt % to 5 wt %.

29. The method of claim 41, wherein the method is for treatment, prophylaxis and/or therapy of microbial diseases and/or inflammatory diseases of the oral cavity, and a composition adminstered additionally comprises one or more flavoring substances and is optionally in form of a chewable compound, a chewing gum, a bonbon, a pastille, a toothpaste, a spray or a mouth wash.

31. The method of claim 41, wherein one or more anti-inflammatory and/or antimicrobial substances are additionally used in a composition administered and/or a composition adminstered is used in combination with solvents, vehicles, excipients, fillers, flavoring substances and/or aroma substances and/or additional ingredients.

36. The method of claim 41, wherein the microorganism is contained in an antimicrobial additive and inflammation in an oropharyngeal space and far infection of the upper respiratory tract and skin are treated.

37. The method of claim 41, wherein the composition is used prophylactically or curatively.

38. The method of claim 41, wherein the administration is orally, sublingually or buccally.

39. A kit for hygiene treatment comprising microorganisms according to claim 1 and physical hygiene devices or equipment, rinses and/or pastes.

40. A method for coaggregating at least with the pathogenic microorganism Staphylococcus pyrogenes comprising:

providing a microorganism belonging to the lactic acid bacterium order or an analog, fragment, derivative, mutant or combinations thereof according to claim 1 and contacting the microorganism with the least one pathogenic microorganism,

wherein the microorganism belonging to the lactic acid bacterium order or an analog, fragment, derivative, mutant or combinations thereof coaggregates with said at least one pathogenic microorganism, wherein the at least one pathogenic microorganism is Staphylococcus pyrogenes.

41. The method of claim 40, wherein said microorganism belonging to the lactic acid bacterium order or the analog, fragment, derivative, mutant or combinations thereof is administered to a patient in need of treatment, prophylaxis, preferably topical treatment and prophylaxis, and/or therapy of microbial diseases or inflammatory diseases of the skin, mucous membranes and oral cavity.

42. The method of claim 40 wherein said microorganism belonging to the lactic acid bacterium order or the analog, fragment, derivative, mutant or combinations thereof is part of a cleaning agent or disinfectant and surfaces are treated with said cleaning agent or disinfectant.

11. (canceled)

13. (canceled)

17. (canceled)

21. (canceled)

22. (canceled)

24. A method for identifying and/or selecting a lactic acid bacterium that coaggregates with Streptococcus pyogenes, wherein the method comprises:

incubating the pathogenic microorganism to form a biofilm,

adding a lactic acid bacterium to be tested and incubation to a mixture for the coaggregation between the pathogenic microorganism and the lactic acid bacterium to be investigated, and

separating the unbound lactic acid bacteria by removing the supernatant and determining the biofilm with regard to coaggregated lactic acid bacteria.

25. The method according to claim 24 additionally comprising:

investigating the biofilm inhibition by the pathogenic microorganisms, wherein the lactic acid bacteria to be investigated are added during the incubation of the biofilm-forming pathogenic microorganisms.

26. The method according to claim 24 additionally comprising:

quantifying the biofilm formation after removing the unbound cells via measurement of an optical density in comparison with a control without addition of the lactic acid bacteria to be tested.

27. (canceled)

28. (canceled)

30. (canceled)

32. (canceled)

33. (canceled)

34. (canceled)

35. (canceled)